NanoLogix to Hold Informational Meeting in Sarasota, Florida
January 31 2007 - 12:45PM
PR Newswire (US)
SHARON, Pa., Jan. 31 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (OTC
Pink Sheets: NNLX) will hold an informational meeting in Sarasota,
Florida on February 12, 2007. Although the company has distributed
proxies to NNLX shareholders, the company intends to utilize the
February meeting solely to increase shareholder understanding of
the company. The company is considering a spin-off of its medical
technology into a separate company. However, this and other matters
will be further clarified and voted upon at a second meeting, which
will be announced at a later date. Mitchell S. Felder, M.D., CEO of
NanoLogix, Inc. stated, "With a new year upon us, now is an
excellent time to update our valued shareholders on the progress of
the company to date, as well as on future growth opportunities. In
2006, the company reached significant milestones in the development
and proprietary design of the hydrogen bioreactors. As an extension
of our production of hydrogen from wastewater, we will begin
offering conversion of gasoline- or diesel- powered engines to
operate cleanly and efficiently on hydrogen gas (H2), through our
relationship with Precision Performance Co. of Ohio. We also are
working on a number of patent applications for the conversion of
gasoline/diesel engines to hydrogen. This year, NanoLogix plans to
pick up the pace of project management, research and development,
and sales and marketing as management pursues its growth strategy
to create a thriving business. With the demand for energy solutions
growing, NanoLogix' focus should help to create substantial value
for shareholders in 2007." About NanoLogix, Inc. NanoLogix is an
industry innovator in the research, development and
commercialization of nano-biotechnologies, applications and
processes. The Company owns or has the rights to 32-patented
technologies and also has 22 pending patent applications. The
Company is currently focused on the production of hydrogen from
agricultural feedstock, industrial wastewater and municipal waste
streams to create new sources of energy. NanoLogix is presently
operating a hydrogen bioreactor at Welch's Food and has recently
signed an agreement with the City of Erie Wastewater Treatment
Plant for a prototype bioreactor at Welch's Food and has recently
signed an agreement with the City of Erie Wastewater Treatment
Plant for a prototype bioreactor installation. Additionally,
NanoLogix develops and markets diagnostic test kits for use in
early detection of infectious diseases, and own a patent for the
non-toxic induction of apoptosis ('cell suicide') for the treatment
of cancer. For more information on the Company, visit:
http://www.nanologix.net/. This press release contains statements,
which may constitute "forward- looking statements" within the
meaning of the Securities Act of 1933 and the Securities Exchange
Act of 1934, as amended by the Private Securities Litigation Reform
Act of 1995. Those statements include statements regarding the
intent, belief or current expectations of NanoLogix, Inc. and
members of its management as well as the assumptions on which such
statements are based. Prospective investors are cautioned that any
such forward-looking statements are not the guarantees of future
performance and involve risks and uncertainties, and that actual
results may differ materially from those contemplated by such
forward-looking statements. The Company undertakes no obligation to
update or revise forward-looking statements to reflect changed
assumptions, the occurrence of unanticipated events or changes to
future operating results. Contacts: NanoLogix, Inc. Investor
Relations 724-346-1302 Andrew Barwicki 516-662-9461 or Peter Clark
OTC Financial Network 781-444-6100 X 629 http://www.otcfn.com/nnlx
DATASOURCE: NanoLogix, Inc. CONTACT: NanoLogix, Inc.,
+1-724-346-1302; or investors, Andrew Barwicki, +1-516-662-9461, or
; or Peter Clark of OTC Financial Network, +1-781-444-6100 X 629,
or , for NanoLogix, Inc. Web site: http://www.nanologix.net/
http://www.otcfn.com/nnlx
Copyright